Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2015 | Advances in monoclonal antibody therapy for multiple myeloma

Joseph Mikhael • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma Antibodies Daratumumab Elotuzumab

At the Myeloma 2015 meeting, Dr Joseph Mikhael (Mayo Clinic, Scottsdale, AZ) discusses the development of monoclonal antibodies (mAbs), including anti-CD38 mAbs, SAR650984 and daratumumab, and anti-SLAMF7 mAb, elotuzumab, for the treatment of multiple myeloma. Clinical results to date suggest these monoclonal antibodies are likely to operate synergistically with other therapies.

More from Joseph Mikhael

2:10
IKEMA trial update: Isatuximab in MM
Joseph Mikhael • 21 Oct 2020
1:53
Transplantation for consolidation in multiple myeloma
Joseph Mikhael • 21 Oct 2020
3:08
Disparities between African American and Caucasian patients with MM
Joseph Mikhael • 21 Oct 2020
2:10
Mentorship in the virtual era
Joseph Mikhael • 21 Oct 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals